Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis.

Derendorf H, Ruebsamen K, Clarke L, Schaeffler A, Kirwan JR.

J Clin Pharmacol. 2013 Mar;53(3):326-33. doi: 10.1177/0091270012444315. Epub 2013 Jan 24.

PMID:
23444285
2.

Delayed-release prednisone - a new approach to an old therapy.

Buttgereit F, Gibofsky A.

Expert Opin Pharmacother. 2013 Jun;14(8):1097-106. doi: 10.1517/14656566.2013.782001. Epub 2013 Apr 18. Review.

PMID:
23594208
3.

How should impaired morning function in rheumatoid arthritis be treated?

Buttgereit F.

Scand J Rheumatol Suppl. 2011;125:28-39. doi: 10.3109/03009742.2011.566438.

PMID:
21529308
4.

Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis.

Kirwan JR, Buttgereit F.

Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv14-20. doi: 10.1093/rheumatology/kes085. Review.

PMID:
22685271
5.

A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.

Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.

Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

PMID:
19843490
6.

Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K.

Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.

PMID:
22129569
7.

Differences in bioavailability between 60 mg of nifedipine osmotic push-pull systems after fasted and fed administration.

Anschütz M, Wonnemann M, Schug B, Toal C, Donath F, Pontius A, Pauli K, Brendel E, Blume H.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):158-70.

PMID:
20137768
10.

Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.

Alten R.

Expert Rev Clin Immunol. 2012 Feb;8(2):123-33. doi: 10.1586/eci.11.95. Review.

PMID:
22288450
11.

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R.

Lancet. 2008 Jan 19;371(9608):205-14. doi: 10.1016/S0140-6736(08)60132-4.

PMID:
18207016
12.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
13.

Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.

Wright CW, Aikman MS, Werts E, Seabolt J, Haeusler JM.

Clin Ther. 2009 Nov;31(11):2722-34. doi: 10.1016/j.clinthera.2009.11.025.

PMID:
20110014
14.
16.

Are modified-release corticosteroids good therapeutic options for patients with RA?

Katz SJ, Russell AS.

Nat Clin Pract Rheumatol. 2008 Jun;4(6):290-1. doi: 10.1038/ncprheum0805. Epub 2008 Apr 22.

PMID:
18431370
17.

Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.

Buttgereit F, Kent JD, Holt RJ, Grahn AY, Rice P, Alten R, Yazici Y.

Bull Hosp Jt Dis (2013). 2015 Jul;73(3):168-77.

19.

Supplemental Content

Support Center